{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:31:59Z","timestamp":1773235919035,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Corcept Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s12325-017-0621-9","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T14:37:54Z","timestamp":1507732674000},"page":"2371-2385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of Ketoconazole on the Pharmacokinetics of Mifepristone, a Competitive Glucocorticoid Receptor Antagonist, in Healthy Men"],"prefix":"10.1007","volume":"34","author":[{"given":"Dat","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Mizne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,11]]},"reference":[{"key":"621_CR1","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1210\/jc.2011-3350","volume":"97","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab. 2012;97:2039\u201349.","journal-title":"J Clin Endocrinol Metab"},{"key":"621_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/oxfordjournals.humrep.a136554","volume":"2","author":"O Heikinheimo","year":"1987","unstructured":"Heikinheimo O, Lahteenmaki PL, Koivunen E, et al. Metabolism and serum binding of RU 486 in women after various single doses. Hum Reprod. 1987;2:379\u201385.","journal-title":"Hum Reprod"},{"key":"621_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/0010-7824(86)90056-9","volume":"34","author":"ML Swahn","year":"1986","unstructured":"Swahn ML, Wang G, Aedo AR, Cekan SZ, Bygdeman M. Plasma levels of antiprogestin RU 486 following oral administration to non-pregnant and early pregnant women. Contraception. 1986;34:469\u201381.","journal-title":"Contraception"},{"key":"621_CR4","unstructured":"Corcept Therapeutics. Korlym\u00ae (mifepristone) 300\u00a0mg tablets [prescribing information]. http:\/\/www.korlym.com\/docs\/KorlymPrescribingInformation.pdf . Accessed 15 June 2017."},{"key":"621_CR5","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/0006-2952(96)00357-7","volume":"52","author":"GR Jang","year":"1996","unstructured":"Jang GR, Wrighton SA, Benet LZ. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. Biochem Pharmacol. 1996;52:753\u201361.","journal-title":"Biochem Pharmacol"},{"key":"621_CR6","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/004982599237976","volume":"29","author":"WN Wu","year":"1999","unstructured":"Wu WN, McKown LA, Moyer MD, Johannsen TB, Takacs AR. In vitro metabolism of mifepristone (RU-486) in rat, monkey and human hepatic S9 fractions: identification of three new mifepristone metabolites. Xenobiotica. 1999;29:1089\u2013100.","journal-title":"Xenobiotica"},{"key":"621_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0022-4731(87)90083-5","volume":"26","author":"O Heikinheimo","year":"1987","unstructured":"Heikinheimo O, Kontula K, Croxatto H, Spitz I, Luukkainen T, Lahteenmaki P. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. J Steroid Biochem. 1987;26:279\u201384.","journal-title":"J Steroid Biochem"},{"key":"621_CR8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0022-3565(24)38021-8","volume":"288","author":"K He","year":"1999","unstructured":"He K, Woolf TF, Hollenberg PF. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486). J Pharmacol Exp Ther. 1999;288:791\u20137.","journal-title":"J Pharmacol Exp Ther"},{"key":"621_CR9","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1172\/JCI3703","volume":"102","author":"JM Lehmann","year":"1998","unstructured":"Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest. 1998;102:1016\u201323.","journal-title":"J Clin Invest"},{"key":"621_CR10","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/JCP.0b013e3182239191","volume":"31","author":"CM Blasey","year":"2011","unstructured":"Blasey CM, Block TS, Belanoff JK, Roe RL. Efficacy and safety of mifepristone for the treatment of psychotic depression. J Clin Psychopharmacol. 2011;31:436\u201340.","journal-title":"J Clin Psychopharmacol"},{"key":"621_CR11","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.biopsych.2006.05.034","volume":"60","author":"C DeBattista","year":"2006","unstructured":"DeBattista C, Belanoff J, Glass S, et al. Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression. Biol Psychiatry. 2006;60:1343\u20139.","journal-title":"Biol Psychiatry"},{"key":"621_CR12","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/sj.npp.1300884","volume":"31","author":"BH Flores","year":"2006","unstructured":"Flores BH, Kenna H, Keller J, Solvason HB, Schatzberg AF. Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology. 2006;31:628\u201336.","journal-title":"Neuropsychopharmacology"},{"key":"621_CR13","unstructured":"ClinicalTrials.gov. Mifepristone and eribulin in patients with metastatic triple negative breast cancer or other specified solid tumors. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02014337?term=mifepristone+and+breast+cancer&rank=4 . Accessed June 14, 2017."},{"key":"621_CR14","unstructured":"ClinicalTrials.gov. A trial of nanoparticle albumin-bound paclitaxel (nab-paclitaxel, Abraxane\u00ae) with or without mifepristone for advanced, glucocorticoid receptor-positive, triple-negative breast cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02788981?term=mifepristone+and+breast+cancer&rank=3 . Accessed June 14, 2017."},{"key":"621_CR15","unstructured":"ClinicalTrials.gov. Enzalutamide and mifepristone in treating patients with metastatic hormone resistant prostate cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02012296 . Accessed June 14, 2017."},{"key":"621_CR16","unstructured":"US Food and Drug Administration. Guidance for industry. Drug interaction studies\u2014study design, data analysis, implications for dosing, and labeling recommendations. http:\/\/www.fda.gov\/downloads\/Drugs\/ucm292362.pdf . Accessed July 15, 2013."},{"key":"621_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2174\/187231209789352085","volume":"3","author":"WL Fitch","year":"2009","unstructured":"Fitch WL, Tran T, Young M, Liu L, Chen Y. Revisiting the metabolism of ketoconazole using accurate mass. Drug Metab Lett. 2009;3:191\u20138.","journal-title":"Drug Metab Lett"},{"key":"621_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1365-2265.1991.tb03547.x","volume":"35","author":"N Sonino","year":"1991","unstructured":"Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D. Ketoconazole treatment in Cushing\u2019s syndrome: experience in 34 patients. Clin Endocrinol. 1991;35:347\u201352.","journal-title":"Clin Endocrinol"},{"key":"621_CR19","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2013-3628","volume":"99","author":"F Castinetti","year":"2014","unstructured":"Castinetti F, Guignat L, Giraud P, et al. Ketoconazole in Cushing\u2019s disease: is it worth a try? J Clin Endocrinol Metab. 2014;99:1623\u201330.","journal-title":"J Clin Endocrinol Metab"},{"key":"621_CR20","unstructured":"Janssen Pharmaceuticals Inc. Nizoral\u00ae tablets [prescribing information]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/018533s040lbl.pdf . Accessed 13 June 2017."},{"key":"621_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/0091270008331196","volume":"49","author":"P Zhao","year":"2009","unstructured":"Zhao P, Ragueneau-Majlessi I, Zhang L, et al. Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study. J Clin Pharmacol. 2009;49:351\u20139.","journal-title":"J Clin Pharmacol"},{"key":"621_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.25.1.1","volume":"25","author":"TK Daneshmend","year":"1984","unstructured":"Daneshmend TK, Warnock DW, Ene MD, et al. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother. 1984;25:1\u20133.","journal-title":"Antimicrob Agents Chemother"},{"key":"621_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1128\/AAC.21.1.151","volume":"21","author":"C Brass","year":"1982","unstructured":"Brass C, Galgiani JN, Blaschke TF, Defelice R, O\u2019Reilly RA, Stevens DA. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother. 1982;21:151\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"621_CR24","unstructured":"US Food and Drug Administration. FDA advises against using oral ketoconazole in drug interaction studies due to serious potential side effects. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm371017.htm . Accessed July 15, 2013."},{"key":"621_CR25","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.4158\/EP15760.OR","volume":"21","author":"KC Yuen","year":"2015","unstructured":"Yuen KC, Williams G, Kushner H, Nguyen D. Association between mifepristone dose, efficacy, and tolerability in patients with Cushing\u2019s syndrome. Endocr Pract. 2015;21:1087\u201392.","journal-title":"Endocr Pract"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0621-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-017-0621-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-017-0621-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T08:52:24Z","timestamp":1750927944000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-017-0621-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["621"],"URL":"https:\/\/doi.org\/10.1007\/s12325-017-0621-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"11 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}